Owen Albin, MD
Infectious Disease · Ann Arbor, MINPI 1629414628
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Biomerieux Inc accounts for 95.5% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $15,864, more than ten times the $1,095 reported in 2022. Among infectious disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $1772.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomerieux Inc$24K
- Shionogi Inc$1K
- Biofire Diagnostics, LLC$26
Across 13 payments — averaging $11,149 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$143K
- Biofire Diagnostics, LLC$2K
What the payments were for
- Consulting fees$14,02056%
- Speaking & faculty fees$2,0268%
- Travel & lodging$8,41834%
- Food & beverage$3501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomerieux Inc | 12 | $23,694 |
| Shionogi Inc | 1 | $1,095 |
| Biofire Diagnostics, LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,815 in reported general payments places this provider in the 95th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JulucaDolutegravir/Rilpivirine | 16 | $75,864 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 19 | $75,106 |
| Daptomycin | 16 | $7,463 |
| Atovaquone | 11 | $3,135 |
| Methenamine Hippurate | 18 | $1,609 |
| Vancomycin Hcl | 14 | $1,427 |
| Doxycycline Hyclate | 13 | $634 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $483 |
| Amoxicillin | 23 | $430 |
| Penicillin V Potassium | 11 | $231 |
| Cephalexin | 13 | $221 |
| Sertraline Hcl | 13 | $156 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Ann Arbor
- Keith KayeAnn Arbor$187K
- David MarkovitzAnn Arbor$24K
- Payal PatelAnn Arbor$23K
- Marisa MiceliAnn Arbor$19K
- Adam LauringAnn Arbor$7K
- Krishna RaoAnn Arbor$3K
- Laraine WasherAnn Arbor$3K
- Suzanne BradleyAnn Arbor$2K
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.